Apoptosis-based evaluation of chemosensitivity in ovarian cancer patients

Journal of the Society for Gynecologic Investigation

Volumn 11, Issue 4, 2004, Pages 252-259

  Flick, Maryann B ^a   O'Malley, David ^a   Rutherford, Thomas ^a   Rodov, Sofya ^a   Kamsteeg, Marijka ^a   Hao, Xiao Ying ^a   Schwartz, Peter ^a   Kacinski, Barry M ^a   Mor, Gil ^a,b  

^a YALE CANCER CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

apoptosis; Carboplatin; caspase 3; chemotherapy; ovarian cancer; paclitaxel

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CARBOPLATIN; CASPASE 3; PACLITAXEL;

APOPTOSIS; ARTICLE; ASCITES FLUID; CANCER CELL; CANCER PATIENT; CANCER RECURRENCE; CELL ISOLATION; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; OVARY CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CARBOPLATIN; CASPASE 3; CASPASES; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; FEMALE; HUMANS; IN SITU NICK-END LABELING; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 2342426207     PISSN: 10715576     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsgi.2003.11.003     Document Type: Article

References (40)

1. Jemal A., Murray T., Samuels A., Ghafoor A., Ward E., Thun M.J. Cancer statistics, 2003. Cancer J Clin. 53:2003;5-26
2. Sevin B.U., Perras J. Tumor heterogeneity and in vitro chemosensitivity testing in ovarian cancer. Am J Obstet Gynecol. 176:1997;759-766
3. Cheng J.Q., Jiang X., Fraser M., et al. Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer Possible involvement of the phosphoinositide-3 kinase/Akt pathway. Drug Resist Update. 5:2002;131-146
4. Ness R., Wisniewski S., Eng H., Christopherson W. Cell viability assay for drug testing in ovarian cancer In vitro kill versus clinical response. Anticancer Res. 22:2002;1145-1149
5. Fanning J., Biddle W., Glodrosen M., et al. Comparison of cisplatin and carboplatin cytotoxicity in human ovarian cancer cell lines using the MTT assay. Gynecol Oncol. 39:1990;119-122
6. Suonio E., Lipponen P., Maenpaa J., Syrjanen K., Kangas L., Tuomisto L. Mitotic index in the subrenal capsule assay as an indicator of the chemosensitivity of ovarian cancer. Cancer Chemother Pharmacol. 41:1997;15-21
7. Eltabbakh G., Piver M., Hempling R., et al. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer. Gynecol Oncol. 70:1998;392-397
8. Orr J., Orr P., Kern D. Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance. Cancer J Sci Am. 5:1999;174-178
9. Konecny G., Crohns C., Pegram M., et al. Correlation of drug response with the ATP tumor chemosensitivity assay in primary FIGO stage III ovarian cancer. Gynecol Oncol. 77:2000;258-263
10. Taylor C., Sargent J., Elgie A., et al. Chemosensitivity testing predicts survival in ovarian cancer. Eur J Gynaecol Oncol. 22:2001;278-282
11. Breidenbach M., Rein D., Mallmann P., Kurbacher C. Individualized long-term chemotherapy for recurrent ovarian cancer after failing high-dose treatment. Anticancer Drugs. 13:2002;173-176
12. Taylor C., Sargent J., Elgie A., Reid F., Alton P., Hill J. The clinical relevance of chemosensitivity testing in ovarian cancer. Cancer Detect Prev. 22:1998;305-312
13. Baguley B., Marshall E., Whittaker J., et al. Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer. Eur J Cancer. 31A:1995;230-237
14. Coley H.M. Drug resistance studies using fresh human ovarian carcinoma and soft tissue sarcoma samples. Keio J Med. 46:1997;142-147
15. Kurbacher C., Mallmann P., Kurbacher J., Hubner H., Krebs D. Chemosensitivity testing in gynecologic oncology. Experiences with an ATP bioluminexcence assay. Geburtshilfe Frauenheilkd. 56:1996;70-78
16. Cortazar P., Johnson B.E. Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer. J Clin Oncol. 17:1999;1625-1631
17. Henkels K., Turchi J. Induction of apoptisis in cisplatin-sensitive and -resistant human ovarian cancer cell lines. Cancer Res. 57:1997;4488-4492
18. Gibb R., Taylor D., Wan T., O'Connor D., Doering D., Gercel-Taylor C. Apoptosis as a measure of chemosensitivity to cisplatin and taxol therapy in ovarian cancer cell lines. Gynecol Oncol. 65:1997;13-22
19. Hannun Y. Apoptosis and the dilemma of cancer chemotherapy. Blood. 89:1997;1845-1853
20. Fisher D. Apoptosis in cancer therapy Crossing the threshold. Cell. 78:1994;539-542
21. Hickman J. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev. 11:1992;121-139
22. Johnstone R., Ruefli A., Lowe S. Apoptosis A link between cancer genetics and chemotherapy. Cell. 108:2002;153-164
23. Caserini C., Pratesi G., Tortoreto M., et al. Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors Preclinical in vitro/in vivo. Clin Cancer Res. 3:1997;955-961
24. Cohen G.M. Caspases The executioners of apoptosis. Biochem J. 326:(Pt 1):1997;1-16
25. Cain K., Bratton S.B., Cohen G.M. The Apaf-1 apoptosome A large caspase-activating complex. Biochimie. 9:2002;203-214
26. Buick R., Pullano R., Trent J. Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res. 45:1985;3668-3676
27. Behrens B., Hamilton T., Masuda H., et al. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res. 47:1987;414-418
28. Kamsteeg M., Rutherford T., Sapi E., et al. Phenoxodiol - An isoflavone analogue-induces apoptosis in chemo-resistant ovarian cancer cells. Oncogene. 22:2003;2611-2620
29. Lounis H., Provencher K., Godbout C., Fink K., Milot M.J., Mes-Masson A.M. Primary cultures of normal and tumoral human ovarian epithelium A powerful tool for basic molecular studies. Exp Cell Res. 215:1994;303-309
30. Markman M., Hoskins W. Responses to salvage chemotherapy in ovarian cancer A critical need for precise definitions of the treated population. J Clin Oncol. 10:1992;513-514
31. Markman M., Bookman M.A. Second-line treatment of ovarian cancer. Oncologist. 5:2000;26-35
32. Song J., Sapi E., Brown W., et al. Roles of Fas and Fas ligand during mammary gland remodeling. J Clin Investig. 106:2000;1209-1220
33. Perez R., Perez K., Handel L., Hamilton T.C. In vitro interactions between platinum analogues in human ovarian-carcinoma cell lines. Cancer Chemother Pharmacol. 29:1992;430-434
34. Jänicke R., Sprengart M., Wati M., Porter A. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem. 273:1998;9357-9360
35. Provencher D., Finstad C., Saigo P., et al. Comparison of antigen expression on fresh and cultured ascites cells and on solid tumors of patients with epithelial ovarian cancer. Gynecol Oncol. 50:1993;78-83
36. Metcalf K., Selby P., Trejdosiewicz L., Southgate J. Culture of ascitic ovarian cancer cells as a clinically-relevant ex vivo model for the assessment of biological therapies. Eur J Gynaecol Oncol. 19:1998;113-119
37. Salmon S., Hamburger A., Soehnlen B., Durie B., Alberts D., Moon T. Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med. 298:1978;1321-1327
38. Sjostrom J., Blomqvist C., von Boguslawski K., et al. The predictive value of bcl-2, bax, bcl-xL, bag-1, fas and fasL for chemotherapy response in advanced breast cancer. Clin Cancer Res. 8:2002;811-816
39. Wu G., El-Deiry W. Apoptotic death of tumor cells correlates with chemosensititvity, independent of p53 or bcl-2. Clin Cancer Res. 2:1996;623-633
40. Oyaizu H., Adachi Y., Yaketani S., Tokunaga R., Fukuhara S., Ikehara S. A crucial role of caspase 3 and caspase 8 in paclitaxel-induced apoptosis. Mol Cell Biol Res Commun. 2:1999;36-41